SCHEMBL859751

SCHEMBL859751

CCOC(=O)CSc1nnnn1-c1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 1.00
SMN1; SMN2 Q16637 7/20 1.00
MAPT P10636 3/20 1.00
HPGD P15428 1/20 1.00
HSD17B10 Q99714 1/20 0.80
USP2 O75604 1/20 0.59
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
MAPK1 P28482 1/20 0.55
ADRB2 P07550 1/20 0.54
HTT P42858 3/20 0.53
POLB P06746 1/20 0.51
NPC1 O15118 1/20 0.49
LMNA P02545 1/20 0.49
GLA P06280 1/20 0.49
PKM P14618 1/20 0.49
TSHR P16473 1/20 0.49
RAB9A P51151 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1493466 0.84 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL859415 0.83 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL13547675 0.82 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL9610139 0.81 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL5958900 0.80 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL859723 0.80 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL6278099 0.79 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL6279104 0.78 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL6281848 0.77 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10
SCHEMBL6278534 0.77 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2MAPTHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 US disclosed
EP-2432774-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 EP disclosed
EP-2432468-A2 METHODS OF MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 EP disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135530-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed
WO-2010135530-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels XDH, PON1, RBP4 ALDH1A1 188/4885SMN1; SMN2 1435/4885MAPT 3061/4885
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT ALDH1A1 167/4885SMN1; SMN2 1281/4885MAPT 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.